Thursday 16 October, 2025
Introduction: There is currently no ‘on the fly’ assessment available for the prediction of influential individuals (InfIDs) and outlying individuals (OutIDs)…
Read moreAbstracts
Pharmacokinetic-pharmacodynamic (PK-PD) modeling of leukocyte dynamics and lymph node size in chronic lymphocytic leukaemia patients treated with ibrutinib
Thursday 16 October, 2025
Objectives: Chronic lymphocytic leukaemia (CLL) is a type of leukaemia that affects developing B-lymphocytes, with a diverse biological and clinical behavior1. …
Read moreA quantitative pharmacology model for CB1 receptor mediated by Gi Gs protein competition
Thursday 16 October, 2025
Objectives: The most intensively studied drug targets are G protein-coupled receptors (GPCRs). There are currently more than 400 drugs targeting…
Read moreA combined model meta-analysis of aggregated and individual FEV1 data from randomized COPD trials
Thursday 16 October, 2025
Introduction: Model-based meta-analysis (MBMA) allows integration of aggregated-level data (AD) from different clinical trials in one pharmacometrics model to assess…
Read morePopulation PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer
Thursday 16 October, 2025
Introduction/Objectives: Camizestrant (AZD9833) is a next-generation oral selective estrogen receptor (ER) degrader and pure ER antagonist currently under Phase 3…
Read moreData-driven model selection for model-informed precision dosing: a case study with vancomycin
Thursday 16 October, 2025
Introduction: Vancomycin is a widely-used antibiotic with a narrow therapeutic range. Elevated levels may lead to nephrotoxicity, while insufficient levels…
Read moreTherapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) combinations: should we monitor the BLI concentration?
Thursday 16 October, 2025
Introduction: In order to restore the activity of β-lactam (BL) drugs against β-lactamase-producing bacteria, several combinations of a BL and…
Read moreA simulation-based evaluation of the pharmacokinetic-pharmacodynamic (PK/PD) index approach for avibactam
Thursday 16 October, 2025
Introduction: β-lactamase inhibitors (BLI) are an increasingly important group of drugs, used to restore the activity of β-lactam (BL) antibiotics…
Read moreA physiologically-based pharmacokinetic model for V937, a novel oncolytic virus, in mice
Thursday 16 October, 2025
Introduction/Objectives: Oncolytic viruses (OVs) represent a novel therapeutic strategy in oncology due to their capability to selectively infect and replicate…
Read moreA physiologically-based pharmacokinetic model to predict systemic and organ exposure for colorectal cancer drugs in clinical settings
Thursday 16 October, 2025
Introduction/Objectives: Colorectal cancer holds the third position among cancers affecting men and the second position among cancers affecting women, being…
Read more